PT  - JOURNAL ARTICLE
AU  - Skittrall, Jordan P.
TI  - Asymptomatic SARS-CoV-2 testing: predictors of effectiveness; risk of increasing transmission
AID  - 10.1101/2020.11.24.20236950
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.24.20236950
4099  - http://medrxiv.org/content/early/2020/11/24/2020.11.24.20236950.short
4100  - http://medrxiv.org/content/early/2020/11/24/2020.11.24.20236950.full
AB  - Testing asymptomatic people for SARS-CoV-2 aims to reduce COVID-19 transmission. Screening programs’ effectiveness depends upon testing strategy, sample handling logistics, test sensitivity, and individual behavior, in addition to dynamics of viral transmission. We investigated the interaction between these factors to determine how to optimize reduction of transmission. We show that under idealistic assumptions 70% of transmission may be averted, but under realistic assumptions only 7% may be averted. We show that programs that overwhelm laboratory capacity or reduce isolation of those with minor symptoms have increased transmission compared with those that do not: programs need to be designed to avoid these issues. Our model allows optimal selection of whom to test, quantifies the balance between accuracy and timeliness, and quantifies potential impacts of behavioral interventions.One Sentence Summary Programs that overwhelm laboratory capacity or reduce isolation of those with minor symptoms have impaired effectiveness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJPS is funded by the Mason Medical Research FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human data are contained in this research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and novel datasets used to produce results are available from the author. Some evaluated datasets are contained in other publications, as referenced in the text.